pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-16-2 |
Genomic Coordinates | chr3: 160404745 - 160404825 |
Description | Homo sapiens miR-16-2 stem-loop |
Comment | This entry represents a second putative hairpin precursor sequence for miR-16, located on chromosome 3 (see also MIR:MI0000070). The sequence was previously named mir-16-3 here and in references . |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-16-2-3p | ||||||||||||||||||
Sequence | 53| CCAAUAUUACUGUGCUGCUUUA |74 | ||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||
Experiments | Cloned | DRVs in miRNA |
|
||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | ZFX | ||||||||||||||||||||
Synonyms | ZNF926 | ||||||||||||||||||||
Description | zinc finger protein, X-linked | ||||||||||||||||||||
Transcript | NM_001178095 | ||||||||||||||||||||
Other Transcripts | NM_001178085 , NM_001178086 , NM_001178084 , NM_003410 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on ZFX | |||||||||||||||||||||
3'UTR of ZFX (miRNA target sites are highlighted) |
>ZFX|NM_001178095|3'UTR 1 TTATTGGCCCTGATGGACATCCTTTGACTGTCTATCCTTGCATGATTTGTGGGAAGAAGTTTAAGTCGAGAGGTTTTTTG 81 AAAAGGCACATGAAAAACCATCCCGAACACCTTGCCAAGAAGAAATACCGCTGTACTGACTGTGATTACACTACCAACAA 161 GAAGATAAGTTTACACAACCACCTGGAGAGCCACAAGCTGACCAGCAAGGCAGAGAAGGCCATTGAATGCGATGAGTGTG 241 GGAAGCATTTCTCTCATGCAGGGGCTTTGTTTACTCACAAAATGGTGCATAAGGAAAAAGGAGCCAACAAAATGCACAAG 321 TGTAAATTCTGTGAATACGAGACAGCTGAACAAGGGTTATTGAATCGCCACCTCTTGGCAGTCCACAGCAAGAACTTTCC 401 TCATATTTGTGTGGAGTGTGGTAAGGGTTTTCGTCACCCGTCAGAGCTCAAAAAGCACATGAGAATCCATACTGGGGAGA 481 AGCCGTACCAATGCCAGTACTGCGAATATAGGTCTGCAGACTCTTCTAACTTGAAAACGCATGTCAAAACTAAGCATAGT 561 AAAGAGATGCCATTCAAGTGTGACATTTGTCTTCTGACTTTCTCGGATACCAAAGAGGTGCAGCAACATGCTCTTATCCA 641 CCAAGAAAGCAAAACACACCAGTGTTTGCATTGCGACCACAAGAGTTCGAACTCAAGTGATTTGAAACGACACATAATTT 721 CAGTTCACACGAAAGACTACCCCCATAAGTGTGACATGTGTGATAAAGGCTTTCACAGGCCTTCAGAACTCAAGAAACAC 801 GTGGCTGCCCACAAGGGCAAAAAAATGCACCAGTGTAGACATTGTGACTTTAAGATTGCAGATCCATTTGTTCTAAGTCG 881 CCATATTCTCTCAGTTCACACAAAGGATCTTCCATTTAGGTGCAAGAGATGTAGAAAGGGATTTAGGCAACAGAGTGAGC 961 TTAAAAAGCATATGAAGACACACAGTGGCAGGAAAGTGTATCAGTGTGAGTACTGTGAGTATAGCACTACAGATGCCTCA 1041 GGCTTTAAACGGCACGTTATTTCCATTCACACGAAAGACTATCCTCACCGGTGTGAGTACTGCAAGAAAGGCTTCCGAAG 1121 ACCTTCAGAAAAGAACCAGCACATAATGCGACATCATAAAGAAGTTGGCCTGCCCTAACAATACTTCTACAGAACGTTTG 1201 TAGAGATATTGGCCTTGAAGCAGAAAATTCATTTTAAAGCCAATCAGTCTCATTCACATACAATACTGTATATTGATTTA 1281 TGCTGTGTACAAATAGAATTATTACTTCTAGTTGACTTTTTTTTAAATATACATTTTGCTCAGTAGTGTGTTCTGAATTC 1361 TATTCAGTTTGTTTAATAAATAGGGAAAACTGGCAACATGCTAGTTACTTTTAATAAAGTAATCCCTGATTCTATACCGA 1441 AGTTTTATATCTTAGAATTTTATATTTATTTAAATATTTACCTTGCTTACCTTGATGGTACTCTTCTAAGACCATTAACT 1521 TAAGGTAACTTTATATTGGTAACTCTGAAAGTATTCATGTTGACTCATTTTTTTCCCCATACATTTCTCACAATAAAATT 1601 GTCAGAGACATCTACTAATATAAATGGGAGATTTTACAGTCAGGTCTAATTATCATAACATGGAAGTCATTTACTTGTCT 1681 TGCTTAATATTTTCAGACCACTTGACAGTGAAAGTTTCCATTTGAGCTGTTGCGTCCCTGGCTTTGCTGAGTAAAGAGCA 1761 GTGGCTGGGTTCGTGTTTACTTTTCAAATATACTTCTTTTGGCTTTCTTTGGATTATTTACATCTTTTGTCAGCGTAGCA 1841 AACTTTTAGAAAACCTTATTGAAAAACTGTGCTTGCTCATGTTGTATTTTGATTATTCTGTCTGTGCGGCTTCATCTTGG 1921 AATGGTTGTGTGCTACAAATGACACTTACTGAGGACTGCATTTTGGAATCTCCTAGAGGTAACTCATGGCTTATAGGATC 2001 TTTTGCAACTTTATGTATGTAAATGTACCCTGAATTATATATATACACATATATATCATGTACCTGTGTGTATTGCTTAT 2081 TTTACATATTTATACACACAACCCCAAGTAGTAGTTGTTTAAAATCTATAATGAAAAGTATTAAATTTACAATAACATGA 2161 AAGATCCAGGGATGCATGAGAGAGCATTTTGTAAGTCATGCTCTTCAGAGAGACTACTCAGGTGAAGAATTAGAAGGAAA 2241 ATAAGGACACTAGTATTTTTAAAGAGTAAAGATATTTTCTTTTAAATATCTTTGGTAATTGAAACATAGAGGTTAAGATG 2321 TTTCTAGGTAGAATGTTTTCATACAATTTCACCTCCATGTCTTTATGTTTTTCTGAAAAGCAAATGAGTATCCAGACATG 2401 ACTCCCACAGTTCTCTTTGAGAAGCCTGAGAGGGAACTCTGTCTTACCTAGTGAGGGGGATGGAAAAGAAGTGATGGCTC 2481 TGTGGACCAGAGAACGGGTGCTAATTATGACTTCACACTCGGCAAGTTCAGGCTGATCTGTTATTTCTCAGTTACAGTTA 2561 GCAAACTTTAAAAACTTAACACTCAAGTTGGCTTTGATTAAAAGGTAAAGATGTGTTTTAAGTGGATAAGGAAAGTCTGA 2641 GGCCTTATTTGGAACATCACTAAGTCTTCCACAGGTTTTTTGTTTGTTTGTTTTTTTTTGTTGTTTTTTTTTCTTAAGAC 2721 GGAGTCTTGCTCTGTTGCCCAGGCTGGACTGCAGTGGTGTGATCACTGCAACCTCTGCAGCTCACTGCAACCTCTGCTTC 2801 CTGGGTTCAAGCAATTATCTGCCTCAGCCTCTCGAGTAGCTGGGATTACAGGCGCCCACCACCACGCCCGGCTAATTTTT 2881 TGTATTTTTAATAGAGATGGGGTTTCACCATCTTGGCCAGGCTGGTCTTGAACCCTGACCTCGTGATCCACCTGCCTCGG 2961 CCTTCCATAGTGCTGGGTTTACAGGCGTGAGCCACCGTGCCCAGACACCACATAGGTCTGAATCAGTGTCATACATTCAT 3041 AAAACAAACTCGGTTAATTAGAACTTGGTTATGTTAAGACGAATCTGGGAGAACAGAAAACAGTTTTTGGGGTCCCTTCA 3121 GTTGGCTATTGGTCCGTATGCATCTAGCACATTGTAGGAGATTTAGAAATTGTCTTCCCACCCGATAGCTGCCTTGTCAC 3201 CTCATTATGGTGCTCCATCCCCTGTGTGCTTAGGTTTTTACCTTTCATCTTTCTCTTTGCCATTGATGTTTGTATTCAAG 3281 AGTTATATTTTTAGGGTTAGAAATCAAAATATTTGGTGTTTGGCAAACCTCTGAAGTGCTAGACTGATTTAGTCTAGTTT 3361 TAAACCAAGTGCTTTAGGCAGGTGTGAACTCCAGCCCAAATGCCAGTCAAAGTCAAGGCATGGGTTTTCCTAGCCTATCT 3441 TATAGGAAATTCCTGTACCTTCTTGGCCCCCATAATGTGTTTTTTTTTTTTTTTTTTTTTTAAACTAACTTACAATTTTG 3521 TGATCCGTGATTCATTGCCCTGCGATTCTTGAAAGCTCTGTCTGTTTTTTTGTGAGAACCTTTAAAATCTCCCTTAATTT 3601 TTATTTTCCCAGAAATAATGTAAAAACACTTAAATGAAAGTGGAAATGTATTAATTTTAAATCCTATAAAATTAATACAG 3681 AAAATATAAATGATTGGGTCATTTAACTATATTTTTTTAAATAAACTGAAAGATAAAGAACACAACACTTCACACATTTT 3761 ATATTTCTCTTACATACTCCGGAATCATACACAGTTCTTTTTAAAGCACAACATTAAAACCTTTAAAAGGTATTTAAGGG 3841 TTTGGTCAAGTGAATATGATAAAACATACTTGTCTGTATAAAGAGAAAATGAAATTGTAGTCACTGTTATGTACTGACAT 3921 TAGTTACAACCTAGTTTTAATTCTTAAAACAATTTTGATTAGCAAAGCTAAAAAAAAATGGATGTTTCAGTTAAATGTTT 4001 TAAAGAGGTACAGATTTTTACAAGGACATAATATAAGTTATTGTTCTGTAGAAATATCCTATTAAATATTGTATGTCCCT 4081 CCCTCTGTACACTTTGTAAAGAAAGTAAAATACATAAAAAGAAAATCATATAGGGATGTGTGACATTATTGTAATTGTGT 4161 ACTTGAGAATAACGTGCAAAAATAAAAATCAGAATATTTTCCTGTTATTGAATGTTTAGTCTATTTGATACCAGTACTAA 4241 GTTAATGCTTTTTCTCAAGGAAAAAAAATGTACAGTTTTTGTAAACCTAATAAACATCAAAAGCAGTGGATTATTTTCAT 4321 CCCCCCATTTCTTAATTTCTTTTTCACAGCAGTGGAATGCAAAGTGCTTGATTGCTTTGAATTTTGTGACTCGGATGCAA 4401 ATACTGGTAATATTTCAGTTCTGTGAATTTGCAAGTAATATTTCAGAGAAGTTAAGAGGTGATTGGTGAGTCCTTTGATG 4481 AGCATGTCCTTGGAATTCATTTTTTCTTTTATCTTCATAAAGGATTTGTTTTATTAGCATCTCCAATTCCCCTGAGATAA 4561 ATTACTCATGCATAAAGTGGTTTTTGAGAGCACTTAAAGTTCATTTCAGTATTAATTTACAGCATATTTAATCAGTGGGG 4641 ACTGTTACCACCTCCACAACAGAAATCATGCCCTCGAGTTACCCCACTGCGCCCAGTTTAGAGGACTAGTAGATGCTAAC 4721 ATACTAGGGAATGGTCATTGCCACAGTTAAAAATCGGCAGTTAAGTAAATGTCAGGAGTCAAAAGAGATAGAGTTGTGCC 4801 ATCTTTGATTTTATAGACAAGATTCTGCAGTTCTTCCAACTGTATGAACAAACGTTTGCCTAATAGTTGAAACAATAAAT 4881 TAAAATTTTAGGTAAATGACGAAGGGAATGTGGTGAATGTCACTGTCCAGAGCCATAAATCAGACAAAACCATACATAGC 4961 ATGCTGAAAAACTTTTGTAATGGAACACCCAACAAATGACACCTAACCTGTCTGTGATCCAACAAGTCCGATAACATGCT 5041 GCTGTATTTGTATTCTCTGGGAATCTCAGTATTAATAATTTCATTTCCCACAAATTCTAGCATTCATGTAAGGAAAAACA 5121 TGGCTAATCAATATCTTAAAGGGGCAATCTTTCAGAGCAGTGGTTTTCAAAGTATGGCCGGACAGCATTGGCAGCATCTT 5201 AATCTCCTGGGACTTTGTTAAAAATGCAAATTCTCAGCCCCACCCTAGTCCTACTGAATTGGGAAACTGGCGTGGGACCC 5281 AGCAGTCTTTGTTTTAACATGTTCTCCAAGTGATTCTGATGCCTGTTCAAACTTGGGAAACACTTTTAGAGCACTTGAGG 5361 AACCTAAAAGATGACTGGTTCAGCATTTTGTGTGGTAGATAAGAAAGAAATTATCACAAAAAATCAGAAATGAACAGTGA 5441 GAGAAAAATAGGACCCCAGACAGTTTATACCTTCCATTTGCTGTTTTAAAAGTGTGAGCCTGCCAAGTCAACAAGTATGC 5521 CTTTAGCGCACATGTAAATAGCCTGCACTTCCTAAATCTCGTGTGGCCTCCCATGGTTACATTCTTCAAAGGTAAACTGA 5601 GTTGAGAGGAAGATTCAGCATTTAAAAGAGAAGGGTTGAAAAAGATTGTGTGTGTGTGTGTGTGTGTTTAATTGGCCCAG 5681 GGTTACTTAAATAAATCATAACCATTTTGCCACATTCTGTAACTGTTTAGCTAAGGTCAAATTAAGTTTACCCTATGGAT 5761 TTTGTTTCATCTTTTGTTTCGTGTATATACTGTTTGCCTTTTTCATAAAAATCTTGGATTTGTTATATATTGTTCCTGTT 5841 ATTTTTGACATCTTTGCTATTGTAAATAAATTACTATTTTGTTTTAAGTTACCCTAGTGGAGTGTTGGCTATAGACAAGG 5921 TATATACTCGAAACGAGGAGACTTAAATCACACAGTTAATGAATTCCCAACTTGTTTGAAGCTGGAGGTGATTCGACTCC 6001 CTTCAGTGGTTCAACACTAATAATAGCACCAAGGAACATGTCACTGGTGCATATAGG Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | HEK293 | ||||||
Disease | 7543.0 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in GSM714644. RNA binding protein: AGO2. Condition:completeT1
... - Kishore S; Jaskiewicz L; Burger L; Hausser et al., 2011, Nature methods. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Kishore S; Jaskiewicz L; Burger L; Hausser et al. - Nature methods, 2011
Cross-linking and immunoprecipitation (CLIP) is increasingly used to map transcriptome-wide binding sites of RNA-binding proteins. We developed a method for CLIP data analysis, and applied it to compare CLIP with photoactivatable ribonucleoside-enhanced CLIP (PAR-CLIP) and to uncover how differences in cross-linking and ribonuclease digestion affect the identified sites. We found only small differences in accuracies of these methods in identifying binding sites of HuR, which binds low-complexity sequences, and Argonaute 2, which has a complex binding specificity. We found that cross-link-induced mutations led to single-nucleotide resolution for both PAR-CLIP and CLIP. Our results confirm the expectation from original CLIP publications that RNA-binding proteins do not protect their binding sites sufficiently under the denaturing conditions used during the CLIP procedure, and we show that extensive digestion with sequence-specific RNases strongly biases the recovered binding sites. This bias can be substantially reduced by milder nuclease digestion conditions.
LinkOut: [PMID: 21572407]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | TZM-bl |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM1462574. RNA binding protein: AGO2. Condition:TZM-bl ami BaL
... - Whisnant AW; Bogerd HP; Flores O; Ho P; et al., 2013, mBio. |
Article |
- Whisnant AW; Bogerd HP; Flores O; Ho P; et al. - mBio, 2013
UNLABELLED: The question of how HIV-1 interfaces with cellular microRNA (miRNA) biogenesis and effector mechanisms has been highly controversial. Here, we first used deep sequencing of small RNAs present in two different infected cell lines (TZM-bl and C8166) and two types of primary human cells (CD4(+) peripheral blood mononuclear cells [PBMCs] and macrophages) to unequivocally demonstrate that HIV-1 does not encode any viral miRNAs. Perhaps surprisingly, we also observed that infection of T cells by HIV-1 has only a modest effect on the expression of cellular miRNAs at early times after infection. Comprehensive analysis of miRNA binding to the HIV-1 genome using the photoactivatable ribonucleoside-induced cross-linking and immunoprecipitation (PAR-CLIP) technique revealed several binding sites for cellular miRNAs, a subset of which were shown to be capable of mediating miRNA-mediated repression of gene expression. However, the main finding from this analysis is that HIV-1 transcripts are largely refractory to miRNA binding, most probably due to extensive viral RNA secondary structure. Together, these data demonstrate that HIV-1 neither encodes viral miRNAs nor strongly influences cellular miRNA expression, at least early after infection, and imply that HIV-1 transcripts have evolved to avoid inhibition by preexisting cellular miRNAs by adopting extensive RNA secondary structures that occlude most potential miRNA binding sites. IMPORTANCE: MicroRNAs (miRNAs) are a ubiquitous class of small regulatory RNAs that serve as posttranscriptional regulators of gene expression. Previous work has suggested that HIV-1 might subvert the function of the cellular miRNA machinery by expressing viral miRNAs or by dramatically altering the level of cellular miRNA expression. Using very sensitive approaches, we now demonstrate that neither of these ideas is in fact correct. Moreover, HIV-1 transcripts appear to largely avoid regulation by cellular miRNAs by adopting an extensive RNA secondary structure that occludes the ability of cellular miRNAs to interact with viral mRNAs. Together, these data suggest that HIV-1, rather than seeking to control miRNA function in infected cells, has instead evolved a mechanism to become largely invisible to cellular miRNA effector mechanisms.
LinkOut: [PMID: 23592263]
|
CLIP-seq Support 1 for dataset GSM714644 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / completeT1, repA |
Location of target site | ENST00000539115.1 | 3UTR | CCAAUCAGUCUCAUUCACAUACAAUACUGUAUAUUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 21572407 / GSE28865 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM1462574 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | TZM-bl / TZM-bl ami BaL |
Location of target site | ENST00000539115.1 | 3UTR | CCAAUCAGUCUCAUUCACAUACAAUACUGUAUA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23592263 / GSE59944 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
75 hsa-miR-16-2-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT004488 | RARB | retinoic acid receptor beta | 3 | 1 | ||||||||
MIRT038707 | NUCKS1 | nuclear casein kinase and cyclin dependent kinase substrate 1 | 1 | 1 | ||||||||
MIRT057208 | PPIF | peptidylprolyl isomerase F | 2 | 4 | ||||||||
MIRT058726 | RSBN1 | round spermatid basic protein 1 | 2 | 8 | ||||||||
MIRT074502 | NFATC2IP | nuclear factor of activated T-cells 2 interacting protein | 2 | 4 | ||||||||
MIRT081544 | ZNF431 | zinc finger protein 431 | 2 | 4 | ||||||||
MIRT096893 | ERBB2IP | erbb2 interacting protein | 2 | 2 | ||||||||
MIRT105124 | MYC | MYC proto-oncogene, bHLH transcription factor | 2 | 2 | ||||||||
MIRT107898 | PTAR1 | protein prenyltransferase alpha subunit repeat containing 1 | 2 | 4 | ||||||||
MIRT109432 | KLHL15 | kelch like family member 15 | 2 | 6 | ||||||||
MIRT166742 | PAPD7 | poly(A) RNA polymerase D7, non-canonical | 2 | 6 | ||||||||
MIRT171257 | YWHAG | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma | 2 | 2 | ||||||||
MIRT192760 | B2M | beta-2-microglobulin | 2 | 2 | ||||||||
MIRT194905 | RBBP6 | RB binding protein 6, ubiquitin ligase | 2 | 8 | ||||||||
MIRT215599 | SUB1 | SUB1 homolog, transcriptional regulator | 2 | 2 | ||||||||
MIRT223632 | ATP6V1C1 | ATPase H+ transporting V1 subunit C1 | 2 | 4 | ||||||||
MIRT241605 | AMOTL1 | angiomotin like 1 | 2 | 4 | ||||||||
MIRT291174 | SH3GLB1 | SH3 domain containing GRB2 like, endophilin B1 | 2 | 2 | ||||||||
MIRT444286 | ABCG2 | ATP binding cassette subfamily G member 2 (Junior blood group) | 2 | 2 | ||||||||
MIRT463285 | ZFX | zinc finger protein, X-linked | 2 | 4 | ||||||||
MIRT471759 | NUS1 | NUS1 dehydrodolichyl diphosphate synthase subunit | 2 | 8 | ||||||||
MIRT479611 | CDC25A | cell division cycle 25A | 2 | 2 | ||||||||
MIRT481497 | ARL6IP1 | ADP ribosylation factor like GTPase 6 interacting protein 1 | 2 | 8 | ||||||||
MIRT483117 | SH3BP5 | SH3 domain binding protein 5 | 2 | 2 | ||||||||
MIRT502279 | GRPEL2 | GrpE like 2, mitochondrial | 2 | 8 | ||||||||
MIRT507838 | CCNT1 | cyclin T1 | 2 | 2 | ||||||||
MIRT508179 | MTRNR2L6 | MT-RNR2-like 6 | 2 | 4 | ||||||||
MIRT510576 | UBE2D3 | ubiquitin conjugating enzyme E2 D3 | 2 | 6 | ||||||||
MIRT517853 | RPS4X | ribosomal protein S4, X-linked | 2 | 4 | ||||||||
MIRT521690 | PRKAA1 | protein kinase AMP-activated catalytic subunit alpha 1 | 2 | 8 | ||||||||
MIRT525070 | FRK | fyn related Src family tyrosine kinase | 2 | 2 | ||||||||
MIRT527082 | UBE2E3 | ubiquitin conjugating enzyme E2 E3 | 2 | 2 | ||||||||
MIRT529552 | EI24 | EI24, autophagy associated transmembrane protein | 2 | 2 | ||||||||
MIRT530426 | SULT1B1 | sulfotransferase family 1B member 1 | 2 | 2 | ||||||||
MIRT533909 | TBC1D15 | TBC1 domain family member 15 | 2 | 2 | ||||||||
MIRT536627 | IPO7 | importin 7 | 2 | 2 | ||||||||
MIRT537647 | ERGIC2 | ERGIC and golgi 2 | 2 | 4 | ||||||||
MIRT538512 | CLCN3 | chloride voltage-gated channel 3 | 2 | 2 | ||||||||
MIRT539219 | ANP32E | acidic nuclear phosphoprotein 32 family member E | 2 | 6 | ||||||||
MIRT539348 | AGO2 | argonaute 2, RISC catalytic component | 2 | 4 | ||||||||
MIRT539954 | CCT4 | chaperonin containing TCP1 subunit 4 | 2 | 2 | ||||||||
MIRT541208 | HOXA10 | homeobox A10 | 2 | 2 | ||||||||
MIRT543216 | TMEM117 | transmembrane protein 117 | 2 | 2 | ||||||||
MIRT543399 | DROSHA | drosha ribonuclease III | 2 | 2 | ||||||||
MIRT546648 | RPS6KA5 | ribosomal protein S6 kinase A5 | 2 | 2 | ||||||||
MIRT546852 | RAB1A | RAB1A, member RAS oncogene family | 2 | 2 | ||||||||
MIRT549917 | MRPS30 | mitochondrial ribosomal protein S30 | 2 | 2 | ||||||||
MIRT552998 | USP46 | ubiquitin specific peptidase 46 | 2 | 2 | ||||||||
MIRT555254 | PREPL | prolyl endopeptidase-like | 2 | 2 | ||||||||
MIRT555956 | NRIP1 | nuclear receptor interacting protein 1 | 2 | 2 | ||||||||
MIRT557095 | HOXA9 | homeobox A9 | 2 | 2 | ||||||||
MIRT561396 | TUBB2A | tubulin beta 2A class IIa | 2 | 2 | ||||||||
MIRT561654 | RNF219 | ring finger protein 219 | 2 | 2 | ||||||||
MIRT563101 | PABPC4L | poly(A) binding protein cytoplasmic 4 like | 2 | 2 | ||||||||
MIRT565979 | RNF44 | ring finger protein 44 | 2 | 2 | ||||||||
MIRT572396 | CCDC14 | coiled-coil domain containing 14 | 2 | 2 | ||||||||
MIRT574400 | TM9SF3 | transmembrane 9 superfamily member 3 | 2 | 2 | ||||||||
MIRT607623 | VSNL1 | visinin like 1 | 2 | 2 | ||||||||
MIRT610645 | CTGF | connective tissue growth factor | 2 | 2 | ||||||||
MIRT623379 | LPP | LIM domain containing preferred translocation partner in lipoma | 2 | 2 | ||||||||
MIRT624687 | AR | androgen receptor | 2 | 2 | ||||||||
MIRT632089 | ALDH1A2 | aldehyde dehydrogenase 1 family member A2 | 2 | 2 | ||||||||
MIRT644216 | CBS | cystathionine-beta-synthase | 2 | 2 | ||||||||
MIRT647841 | BID | BH3 interacting domain death agonist | 2 | 2 | ||||||||
MIRT651649 | WASF2 | WAS protein family member 2 | 2 | 2 | ||||||||
MIRT689064 | AGMAT | agmatinase | 2 | 2 | ||||||||
MIRT698150 | TNPO1 | transportin 1 | 2 | 2 | ||||||||
MIRT700516 | PTPN14 | protein tyrosine phosphatase, non-receptor type 14 | 2 | 2 | ||||||||
MIRT704081 | DYRK2 | dual specificity tyrosine phosphorylation regulated kinase 2 | 2 | 2 | ||||||||
MIRT705970 | ACBD5 | acyl-CoA binding domain containing 5 | 2 | 2 | ||||||||
MIRT715694 | COMMD3-BMI1 | COMMD3-BMI1 readthrough | 2 | 2 | ||||||||
MIRT717184 | BMI1 | BMI1 proto-oncogene, polycomb ring finger | 2 | 2 | ||||||||
MIRT724607 | AP3B1 | adaptor related protein complex 3 beta 1 subunit | 2 | 2 | ||||||||
MIRT724854 | IGFBP5 | insulin like growth factor binding protein 5 | 2 | 2 | ||||||||
MIRT725401 | LRIG2 | leucine rich repeats and immunoglobulin like domains 2 | 2 | 2 |
miRNA-Drug Associations | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|